Focus on Anticoagulation Care

Back to articles

Optimal duration of anticoagulation after thrombotic event remains unclear

KEY POINT

In patients with a first pulmonary embolism (PE) who had already received 6 months of warfarin, an additional 18 months of warfarin led to a decreased risk of recurrent venous thromboembolism (VTE), compared with patients who received only 6 months of warfarin, but risks did not differ between treatment groups after warfarin discontinuation.